T0	Interventions 0 55	Rituximab plus concurrent infusional EPOCH chemotherapy
T1	Interventions 466 732	rituximab (375 mg/m(2)) given either concurrently before each infusional etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone (EPOCH) chemotherapy cycle or sequentially (weekly for 6 weeks) after completion of all chemotherapy in HIV-associated NHL.
T2	Interventions 733 738	EPOCH
T3	Interventions 786 846	etoposide, doxorubicin, and vincristine plus oral prednisone
T4	Interventions 877 893	cyclophosphamide
T5	Interventions 1408 1450	concurrent rituximab plus infusional EPOCH